PERSPECTIVE THERAPEUTICS INC (CATX)
Health Care · Targeted alpha therapy / radiotherapy oncology · Nyse Mkt Llc
A targeted alpha therapy biotech advancing novel oncology candidates through clinical development toward potential FDA approval and commercialization.
What PERSPECTIVE THERAPEUTICS INC does
Perspective Therapeutics is a clinical-stage biopharmaceutical company developing targeted alpha therapy (TAT) drug candidates for oncology. The company is focused on developing novel alpha-emitting therapeutics designed to treat cancer, with lead programs including PSV359. The company operates manufacturing infrastructure and clinical development programs, with cash resources expected to fund operations into late 2027.
Themes: ["Targeted alpha therapy / oncology","Clinical-stage biotech","Cancer immunotherapy"]
Fundamentals
- Price$3.17 as of 2026-07-09 close
- Market cap$362M as of 2026-07-10
- 1-year return-16.1% as of 2026-07-09 close
- Net margin-17982.7% as of 2026-07-10
- Gross margin+23.0% as of 2026-07-10
- ROE-41.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-58.0% as of 2026-07-10
- Revenue CAGR (3y)+11.4% SEC XBRL
- Beta1.76 as of 2026-07-10
Key risks (from latest filing)
["Preclinical and clinical trial timing, progress, and results are uncertain; regulatory approvals from FDA are not guaranteed, including Fast Track designation for PSV359","Manufacturing scalability and commercial viability of drug product manufacturing methods remain unproven at scale for clinical and commercial demands","Company is unprofitable with significant accumulated deficit (-$361 million as of March 31, 2026) and negative cash burn; funding needs extend into late 2027 with uncertain path to revenue generation"]
Competitors & peers
- Actinium Pharmaceuticals
- Novartis (oncology division)
- Bayer (oncology division)
- Roche/Genentech
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.